查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615417

學名藥市場：按類型、給藥途徑、適應症、藥物、分銷分類 - 全球預測 2025-2030

Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Drug, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年學名藥市場規模為2,991.6億美元，預計2024年將達3,162.7億美元，複合年成長率為5.91%，2030年將達4,474.5億美元。

學名藥市場的範圍和定義包括基於專利保護期滿的原廠藥開發的、可以由多個製造商生產且不侵犯知識產權的藥品。對學名藥的需求在於其可負擔性和可用性，透過提供昂貴的品牌藥的成本效益替代品來幫助降低醫療成本並擴大患者的可及性。其應用涵蓋廣泛的治療領域，從糖尿病、高血壓等慢性疾病到急性感染疾病，在醫院、診所和零售藥局都有大量存在。最終用途包括優先考慮具有成本效益的治療方案的個別患者、醫療保健提供者和政府醫療保健系統。影響該市場的關鍵成長要素包括慢性病盛行率上升、新興國家醫療保健支出增加以及有利於學名藥快速核准的法規環境的發展。

主要市場統計
基準年[2023] 2991.6億美元
預計年份 [2024] 3162.7億美元
預測年份 [2030] 4474.5億美元
複合年成長率（%） 5.91%

隨著醫療基礎設施不斷擴大，新興國家的開拓市場以及生物相似藥領域存在著成長機會，特別是在生物製藥預計即將專利到期的情況下。公司可以透過投資策略聯盟、製造能力和有針對性的行銷來利用這些機會。然而，激烈的市場競爭、嚴格的監管要求以及與藥品品質和召回相關的問題等限制可能會阻礙成長。定價壓力以及平衡盈利和負擔能力的需求也帶來了挑戰。

創新和研發包括藥物輸送系統的進步、複雜學名藥的開發以及製造流程的永續性。透過專注於利基治療領域並利用人工智慧和巨量資料進行藥物開發和最佳化來獲得市場開拓。市場動態是動態的、競爭性的，需要不斷適應監管變化和市場需求。為了利用這些動態，公司必須優先考慮強大的品管系統和投資專門的學名藥，從而在擁擠的市場環境中脫穎而出。

市場動態：揭示快速發展的學名藥市場的關鍵市場洞察

供需的動態交互作用正在改變學名藥市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病盛行率上升以及對具有成本效益的藥物的需求
    • 政府對學名藥的支持
    • 透過線上藥局增加學名藥的供應
  • 市場限制因素
    • 病人和醫生對品牌藥物的偏好
  • 市場機會
    • 與學名藥開發相關的持續研究和開發活動
    • 專利到期和戰略長期聯盟增加以生產學名藥
  • 市場挑戰
    • 對品質和製造差異的擔憂

波特五力：駕馭學名藥市場的策略工具

波特五力框架是了解學名藥市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對學名藥市場的影響

外部宏觀環境因素對學名藥市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解學名藥市場競爭狀況

對學名藥市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣供應商在學名藥市場績效評估

FPNV定位矩陣是評估學名藥市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製學名藥市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，學名藥市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的增加和對具有成本效益的藥物的需求
      • 政府對學名藥的優惠支持
      • 透過線上藥局增加學名藥的可得性
    • 抑制因素
      • 病人和醫生對品牌藥物的偏好
    • 機會
      • 與學名藥開發相關的持續研發活動
      • 專利到期並增加製造學名藥的戰略長期夥伴關係
    • 任務
      • 對品質和製造差異的擔憂
  • 市場區隔分析
    • 類型：擴大應用於複雜和慢性疾病的治療
    • 分銷：由於便利性、可近性和具競爭力的價格，網路藥局越來越受青睞。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章學名藥市場：按類型

  • 簡單非專利
  • 特殊非專利

第7章學名藥市場：依管理途徑

  • 吸入式
  • 可注射的
  • 口服

第8章學名藥市場（按適應症）

  • 癌症
  • 心血管疾病
  • 中樞神經系統疾病
  • 糖尿病
  • 消化系統疾病
  • 荷爾蒙與相關疾病
  • 感染疾病
  • 呼吸系統疾病

第9章學名藥市場（按藥品）

  • Acetazolamide
  • 阿維A
  • Atorvastatin
  • 阿奇黴素
  • Carbamazepine
  • 西酞普蘭
  • Clopidogrel
  • 多奈哌齊
  • escitalopram
  • Esomeprazole
  • Fluticasone
  • Gabapentin
  • 氫氯噻嗪
  • 左旋甲狀腺素
  • Lisinopril
  • 氯沙坦
  • 奧美拉唑
  • Posaconazole
  • rosuvastatin
  • 舍曲林
  • Simvastatin
  • Tamsulosin
  • Warfarin

第10章學名藥市場經銷商

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區學名藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲學名藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • BDR Pharma 推出治療真菌感染疾病的學名藥，價格僅為三分之一
    • Amneal 推出已獲批准的非專利Xyrem（奧昔巴特鈉），並獲得 FDA核准其五種複合非專利
    • Mediplus Health Service 推出自有品牌學名藥
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals Inc
  • Aspen Holdings
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Cipla Ltd
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc.
  • Fresenius SE & Co. KGaA.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mylan NV by Viatris Inc.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis Group
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Zydus Lifesciences Ltd
Product Code: MRR-F6513A06BE93

The Generic Drugs Market was valued at USD 299.16 billion in 2023, expected to reach USD 316.27 billion in 2024, and is projected to grow at a CAGR of 5.91%, to USD 447.45 billion by 2030.

The scope and definition of the generic drugs market involve pharmaceuticals developed based on brand-name drugs whose patent protection has expired, allowing production by multiple manufacturers without intellectual property infringement. The necessity of generic drugs lies in their affordability and accessibility, offering cost-effective alternatives to expensive brand-name medications, thereby instrumental in reducing healthcare costs and expanding patient access. Their application spans a vast array of therapeutic areas, from chronic conditions like diabetes and hypertension to acute infections, contributing to their substantial presence in hospitals, clinics, and retail pharmacies. The end-use scope includes individual patients, healthcare providers, and governmental healthcare systems prioritizing cost-effective treatment options. Key growth factors influencing this market include the rising prevalence of chronic diseases, increased healthcare expenditure in emerging economies, and a supportive regulatory environment that encourages the expedited approval of generics.

KEY MARKET STATISTICS
Base Year [2023] USD 299.16 billion
Estimated Year [2024] USD 316.27 billion
Forecast Year [2030] USD 447.45 billion
CAGR (%) 5.91%

Opportunities for growth are present in untapped markets within developing countries where healthcare infrastructure is expanding, and in the biosimilar segment, particularly with the anticipated wave of biologic patent expirations. Companies can leverage these opportunities by investing in strategic collaborations, manufacturing capabilities, and targeted marketing. However, limitations such as intense market competition, stringent regulatory requirements, and issues related to drug quality and recalls can impede growth. Challenges also stem from pricing pressures and the need for maintaining a balance between profitability and affordability.

Innovation and research areas include advancements in drug delivery systems, development of complex generics, and sustainability in manufacturing processes. Market growth can be fueled by focusing on niche therapeutic areas and leveraging AI and big data for drug development and optimization. The nature of the generic drugs market is dynamic and competitive, with a constant need for adaptation to regulatory changes and market demands. To capitalize on these dynamics, organizations should prioritize robust quality management systems and invest in specialty generics to differentiate themselves in the crowded market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Drugs Market

The Generic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases and the need for cost-effective medications
    • Favorable government support for generic drugs
    • Growing availability of generic drugs through online pharmacies
  • Market Restraints
    • Preference for branded drugs by patients and physicians
  • Market Opportunities
    • Ongoing R&D activities associated with the development of generic drugs
    • Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
  • Market Challenges
    • Concerns associated with quality and manufacturing variability

Porter's Five Forces: A Strategic Tool for Navigating the Generic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Drugs Market

A detailed market share analysis in the Generic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Drugs Market

A strategic analysis of the Generic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Amneal Pharmaceuticals Inc, Aspen Holdings, Aurobindo Pharma Limited, Baxter International Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin Limited, Mylan N.V. by Viatris Inc., Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi S.A., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Zydus Lifesciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Simple Generic and Specialty Generic.
  • Based on Route of Administration, market is studied across Inhalable, Injectable, and Oral.
  • Based on Indication, market is studied across Cancer, Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Gastrointestinal Diseases, Hormones & Related Diseases, Infectious Diseases, and Respiratory Diseases.
  • Based on Drug, market is studied across Acetazolamide, Acitretin, Atorvastatin, Azithromycin, Carbamazepine, Citalopram, Clopidogrel, Donepezil, Escitalopram, Esomeprazole, Fluticasone, Gabapentin, Hydrochlorothiazide, Levothyroxine, Lisinopril, Losartan, Omeprazole, Posaconazole, Rosuvastatin, Sertraline, Simvastatin, Tamsulosin, and Warfarin.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and the need for cost-effective medications
      • 5.1.1.2. Favorable government support for generic drugs
      • 5.1.1.3. Growing availability of generic drugs through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with the development of generic drugs
      • 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding applications of for treating complex and chronic conditions
    • 5.2.2. Distribution: Emerging preference for online pharmacies for convenience, accessibility, and competitive pricing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Simple Generic
  • 6.3. Specialty Generic

7. Generic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalable
  • 7.3. Injectable
  • 7.4. Oral

8. Generic Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Central Nervous System Disorders
  • 8.5. Diabetes
  • 8.6. Gastrointestinal Diseases
  • 8.7. Hormones & Related Diseases
  • 8.8. Infectious Diseases
  • 8.9. Respiratory Diseases

9. Generic Drugs Market, by Drug

  • 9.1. Introduction
  • 9.2. Acetazolamide
  • 9.3. Acitretin
  • 9.4. Atorvastatin
  • 9.5. Azithromycin
  • 9.6. Carbamazepine
  • 9.7. Citalopram
  • 9.8. Clopidogrel
  • 9.9. Donepezil
  • 9.10. Escitalopram
  • 9.11. Esomeprazole
  • 9.12. Fluticasone
  • 9.13. Gabapentin
  • 9.14. Hydrochlorothiazide
  • 9.15. Levothyroxine
  • 9.16. Lisinopril
  • 9.17. Losartan
  • 9.18. Omeprazole
  • 9.19. Posaconazole
  • 9.20. Rosuvastatin
  • 9.21. Sertraline
  • 9.22. Simvastatin
  • 9.23. Tamsulosin
  • 9.24. Warfarin

10. Generic Drugs Market, by Distribution

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. BDR Pharma launches generic drug for fungal infections at 1/3rd the cost
    • 14.3.2. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.3. Mediplus Health Services launches own brand of generic medicines
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Ltd.
  • 3. Amneal Pharmaceuticals Inc
  • 4. Aspen Holdings
  • 5. Aurobindo Pharma Limited
  • 6. Baxter International Inc.
  • 7. Cipla Ltd
  • 8. Dr. Reddy's Laboratories Ltd.
  • 9. Eli Lilly and Company
  • 10. Endo International plc.
  • 11. Fresenius SE & Co. KGaA.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. Hikma Pharmaceuticals PLC.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Lupin Limited
  • 18. Mylan N.V. by Viatris Inc.
  • 19. Pfizer Inc.
  • 20. Sandoz International GmbH by Novartis Group
  • 21. Sanofi S.A.
  • 22. STADA Arzneimittel AG
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Teva Pharmaceuticals Industries Ltd.
  • 25. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY ACITRETIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY FLUTICASONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY LEVOTHYROXINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY LISINOPRIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC DRUGS MARKET SIZE, BY LOSARTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GENERIC DRUGS MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL GENERIC DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL GENERIC DRUGS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 180. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. NIGERIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 200. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NORWAY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 204. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 205. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. POLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 209. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 210. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. QATAR GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 214. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 215. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. RUSSIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 219. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 220. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 224. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 230. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SPAIN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 234. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 235. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. SWEDEN GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 239. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 240. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 244. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 245. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. TURKEY GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 249. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 250. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 254. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 261. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023